Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT05371145
PHASE1/PHASE2
Carnosine for Peripheral Arterial Disease Patients
Sponsor: Shahid Baba
View on ClinicalTrials.gov
Summary
Oral supplementation of L-carnosine will increase muscle carnosine, stabilize HIF1-alpha promote angiogenesis, and thus improve the functioning of lower extremities in PAD patients.
Official title: Carnosine for Peripheral Arterial Disease Patients (Car-PAD)
Key Details
Gender
MALE
Age Range
50 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2023-03-01
Completion Date
2024-12-30
Last Updated
2024-07-22
Healthy Volunteers
No
Conditions
Interventions
BIOLOGICAL
Carnosine
Determine whether carnosine supplementation (2 g/day) for 3 months in peripheral arterial disease patients improves 6MWT ability.
Locations (1)
University of Louisville
Louisville, Kentucky, United States